Silence Therapeutics Plc

Silence Therapeutics (SLN)

Buy
Sell
Company name:Silence Therapeutics Plc
Company Description:A group engaged in biotechnology research and development in the UK Germany and the United States
EPIC:SLNTrading Currency:GBX
Market Sector:AE50ISIN:GB00B9GTXM62
Market Segment:AMSMShare Type:DE
WWW Address:http://www.silence-therapeutics.com/Description:ORD 5P
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Offer Open High Low Volume
 580.00 images.advfn.com/imagesnew/2/gb/up 26.0 [4.69] 576.00 580.00 566.00 582.00 554.00 315,599
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 481.38 83.00 -0.16 -26.10 - - - 605.00 - 330.00

Silence Therapeutics Key Figures

(at previous day's close)
Market Cap.481.38m
Shares In Issue83.00m
Prev. Close554.00
PE Ratio- 
Dividend Yield-%
EPS - basic-26.10p
Dividend PS-p
Dividend Cover- 
Cash Flow PS2.08p
Return On Equity (ROE)-93.65%
Operating Margin-9,372.95%
PEG Factor- 
EPS Growth Rate0.38%
Dividends PS Growth Rate-%
Net Debt11.65m
Gross Gearing54.62%
Quick Assets37.47m
Net Working Capital27.81m
Intangibles / Fixed Assets89.71%
Turnover PS0.29p
Pre-Tax Profit PS-27.56p
Retained Profit PS-23.59p
Cash PS16.28p
Net Cash PS4.65p
Net Tangible Asset Value PS *15.88p
Net Asset Value PS25.19p
Spread4.00 (0.69%) 
* Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies.

Silence Therapeutics Balance Sheet

LSE:SLN:Liabilities+EQLSE:SLN:Assets

Share Price Performance

Sample Period †HighLow
1 week582.00516.00
4 weeks582.00455.00
12 weeks582.00330.00
1 year605.00330.00

Share Price Chart (5 years)

Silence Therapeutics Historic Returns

Period †OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week548.0032.005.84516.000.09548.38
4 weeks455.00125.0027.47455.000.31520.33
12 weeks331.00249.0075.23330.000.22480.82
26 weeks489.0091.0018.61330.000.13473.09
1 year370.00210.0056.76330.000.17438.80
3 years195.00385.00197.4440.000.14279.85
5 years145.00435.00300.0040.000.12246.02
† periods calculated are whole weeks rather than calendar months

Silence Therapeutics Key Management Ratios

Silence Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio448.62 
PE Ratio- 
Tobin's Q Ratio 11.33 
Tobin's Q Ratio (excl. intangibles)13.94 
Dividend Yield-%
Market-to-Book Ratio23.02 
Price-to-Pre-Tax Profit PS-21.05 
Price-to-Retained Profit PS-24.58 
Price-to-Cash Flow PS278.74 
Price-to-Sales PS1,972.86 
Price-to-Net Tangible Asset Value PS36.52 
Price-to-Cash PS35.62 
Net Working Capital PS33.51 
Price Pct to Working Capital PS17.31%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Silence Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio42.60%
Debt-to-Equity Ratio0.74 
Debt-to-Equity Ratio (excl. Intgbl)1.18 
Debt-to-Equity Market Value0.03 
Net Gearing25.29%
Net Gearing (excl. Intangibles)30.39%
Gross Gearing54.62%
Gross Gearing (excl. Intangibles)65.63%
Gearing Under 1 Year20.95%
Gearing Under 1 Year (excl. Intgbl)25.17%
Assets/Equity2.20 
Cash/Equity64.64 
(Liquidity Ratios)
Net Working Capital to Total Assets60.36%
Current Ratio3.88 
Quick Ratio (Acid Test)3.88 
Liquidity Ratio1.40 
Cash & Equiv/Current Assets36.07%
(Solvency Ratios)
Enterprise Value483.38m
CFO/Sales7.08 
CFO/Attributable Profit- 
CFO/Assets0.04 
CFO/Debt0.07 
Total Debt/Equity Market Value0.05 
Total Debt/Sales103.15 
Total Debt/Pre-Tax Profit-1.10 
Total Debt25.17m
Total Debt/Net Current Assets0.90%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs9 
Beta (60-Mnth)Beta (36-Mnth)
-0.1649-0.2755

Silence Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-62.79%
Return On Assets (ROA)-46.10%
Net Profit Margin-8,025.41%
Assets Turnover0.01 
Return On Equity (ROE)-93.65%
Return On Investment (ROI)-54.79%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-8,025.41%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.01 
Fixed Assets Turnover0.03 
Current Assets Turnover0.01 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales174.10 
Debtors-to-Sales1,054.10%
Debt Collection Period3,847.46Days

Silence Therapeutics Dividends

Sorry No Data Available

Silence Therapeutics Fundamentals
 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
turnover0.77-0.02---0.24-m
pre tax profit-10.36--3.78--20.53--22.87-m
attributable profit-8.44--1.62--18.41--19.58-m
retained profit-8.44--1.62--18.41--19.58-m
eps - basic (p)-12.10 -2.30 -26.20 -26.10 
eps - diluted (p)-12.10 -2.30 -26.20 -26.10 
dividends per share- - - - 

Silence Therapeutics Balance Sheet

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
LSE:SLN:Liabilities+EQLSE:SLN:AssetsLSE:SLN:Liabilities+EQLSE:SLN:AssetsLSE:SLN:Liabilities+EQLSE:SLN:AssetsLSE:SLN:Liabilities+EQLSE:SLN:Assets
 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
ASSETS
fixed assets fixed assets1.382.46%1.172.13%0.922.37%0.611.33%m
intangibles intangibles7.7513.90%8.0614.65%8.1921.06%7.7316.77%m
fixed investments fixed investments4.427.92%0.320.58%0.280.71%0.280.60%m
current assets - other current assets - other--%--%5.9215.23%20.8945.33%m
stocks stocks--%--%--%--%m
debtors debtors3.235.79%2.724.94%2.085.35%3.066.65%m
cash & securities cash & securities39.0169.92%42.7577.71%21.4955.28%13.5229.33%m
TOTAL55.79100%55.01100%38.89100%46.08100%m
LIABILITIES
creditors - short creditors - short1.612.89%2.664.83%3.839.85%9.6520.95%m
creditors - long creditors - long--%--%--%15.5233.67%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL1.612.89%2.664.83%3.839.85%25.1754.62%m
EQUITY
ord cap, reserves ord cap, reserves54.1897.11%52.3595.17%35.0690.15%20.9145.38%m
prefs, minorities prefs, minorities--%--%--%--%m
TOTAL54.1897.11%52.3595.17%35.0690.15%20.9145.38%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Silence Therapeutics Cash Flow Statement

31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
Operating CF-10.07-9.60-16.761.73m
Pre-Financing CF-14.743.42-21.59-13.29m
Retained CF-14.843.46-21.25-8.02m

Silence Therapeutics Brokers

NameActivityTypeMnemonicCode
Nomura Code Securities LimitedMarket Maker(MME)Broker/DealerCODECODCGB21
Collins Stewart Europe LimitedMarket Maker(MME)Broker/DealerCSCSCSTEGB21
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MME)Broker/DealerJEFFJEFFGB2X
Liberum Capital LimitedMarket Maker(MME)Broker/DealerLIBCLCAPGB21
Shore Capital Stockbrokers LtdMarket Maker(MME)Broker/DealerSCAPSHOCGB21
Merrill Lynch InternationalMarket Maker(MME)Broker/DealerMLSBSNCSGB2LBIC
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
ADVFN Advertorial
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210127 04:52:59